11 results on '"Aiko Hirano"'
Search Results
2. Optimal dose of intravenous cyclophosphamide during remission induction therapy in ANCA-associated vasculitis: A retrospective cohort study of J-CANVAS.
- Author
-
Hideaki Sofue, Takashi Kida, Aiko Hirano, Satoshi Omura, Masatoshi Kadoya, Daiki Nakagomi, Yoshiyuki Abe, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, and Ryo Yanai
- Subjects
REMISSION induction ,CYCLOPHOSPHAMIDE ,VASCULITIS ,REGRESSION analysis ,CONFIDENCE intervals - Abstract
Objectives: To identify the optimal dose of intravenous cyclophosphamide (IVCY) for induction therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Methods: We retrospectively assessed patients with antibody-associated vasculitis who received IVCY every 2–3 weeks during the remission induction phase. The associations of the IVCY dose with infection-free survival and relapse-free survival were analysed using a Cox regression model. We compared patients in three categories: very low-dose (VLD), low-dose (LD), and conventional dose (CD) (<7.5 mg/kg, 7.5–12.5 mg/kg, and >12.5 mg/kg, respectively). The non-linear association between IVCY dose and the outcomes was also evaluated. Results: Of the 80 patients (median age 72 years), 12, 42, and 26 underwent the VLD, LD, and CD regimens, respectively, of whom 4, 3, and 7 developed infection or died. The adjusted hazard ratios for infection or death were 4.3 (95% confidence interval (CI) 0.94–19.8) for VLD and 5.1 (95% CI 1.21–21.3) for CD, compared with LD. We found the hazard ratio for infection or death increased when the initial IVCY dose exceeded 9 mg/kg. Relapse-free survival did not differ clearly. Conclusion: Low-dose IVCY (7.5–12.5 mg/kg) may result in fewer infections and similar relapse rates compared with the conventional regimen (>12.5 mg/kg). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus
- Author
-
Aiko Hirano, Kazuki Fujioka, Takashi Kida, Satoshi Omura, Hideaki Sofue, Aki Sakashita, Tomoya Sagawa, Yu Isoda, Akiko Kasahara, Risa Sagawa, Wataru Fujii, Takahiro Seno, Makoto Wada, Masataka Kohno, and Yutaka Kawahito
- Subjects
Rheumatology - Abstract
Belimumab is a therapeutic medication that inhibits the B-cell-activating factor (BAFF) used for systemic lupus erythematosus (SLE); however, the response sometimes varies among individuals, even when patients are stratified based on general clinical characteristics. Therefore, we focused on immunological phenotypic changes with belimumab, investigated their association with subsequent clinical courses, and sought to identify relevant immunological indicators to stratify patients who would benefit from belimumab. We assessed changes in B and T cell phenotypes, as well as BAFF-related factors, such as levels of BAFF and a proliferation-inducing ligand, and expression of three BAFF receptors: BAFF receptor (BAFF-R), B-cell maturation antigen (BCMA), transmembrane activator and cyclophilin ligand interactor (TACI), in 19 patients with SLE who were treated with belimumab before and 3 months after treatment. First, to visualize patterns in complex and diverse data, we summarized B cell changes such as subsets and BAFF receptor expressions into two axes, the first and second principal components (PC1 and PC2), and characterized broad phenotypic changes by cluster analysis. Next, we evaluated whether the B cell changes represented by PC1 and PC2 were associated with other concurrent phenotypic changes, baseline factors, and treatment response at 6 months. We found that lower PC2, indicating increased BAFF-R expression and decreased percentage of naïve B cells, was associated with a subsequent therapeutic response at 6 months (odds ratio 5.3, 95% confidence interval 1.2–24, p = .031). Furthermore, higher percentages of effector memory CD3+CD4+ T cells at baseline were associated with lower PC2 and therapeutic response. Further analysis revealed that increased PC1, as reflected by increased BCMA and TACI expression and an increase in the percentage of class-switched memory B cells, was associated with both T and B cell activation. Although belimumab is a B-cell targeted therapy, it can also influence T-cell phenotypes. Thus, early B cell changes could be used to predict treatment response, and their changes could be predicted from baseline T cell phenotypes, indicating the importance of B and T cell interactions.
- Published
- 2022
4. Ligand compatibility of salacinol-type α-glucosidase inhibitors toward the GH31 family
- Author
-
Fumihiro Ishikawa, Kiyofumi Ninomiya, Shinya Nakamura, Toshio Morikawa, Weijia Xie, Genzoh Tanabe, Yuuto Yoshimori, Aiko Hirano, Osamu Muraoka, Katsuki Takashima, Kana Nishida, Shinsuke Marumoto, and Isao Nakanishi
- Subjects
0303 health sciences ,03 medical and health sciences ,010405 organic chemistry ,Chemistry ,Stereochemistry ,General Chemical Engineering ,α glucosidase ,Compatibility (geochemistry) ,General Chemistry ,Ligand (biochemistry) ,01 natural sciences ,030304 developmental biology ,0104 chemical sciences - Abstract
We show that salacinol-type α-glucosidase inhibitors are ligand-compatible with the GH 31 family. Salacinol and its 3′-O-benzylated analogs inhibit human lysosomal α-glucosidase at submicromolar levels. Simple structure-activity relationship studies reveal that the salacinol side-chain stereochemistry significantly influences binding to GH31 α-glucosidases.
- Published
- 2021
5. Body measurement of riding horses with a versatile tablet-type 3D scanning device
- Author
-
Suzuka Torii, Akihiro Matsuura, Aiko Hirano, Shigeru Morita, Yoshio Kiku, and Maiko Dan
- Subjects
conformation ,Scanner ,Waist ,Full Paper ,Correlation coefficient ,Equine ,Withers ,3d scanning ,Circumference ,Girth (geometry) ,horse ,light detection and ranging (LiDAR) ,non-contact ,3d image ,3D images ,Mathematics ,Biomedical engineering - Abstract
The measurement of various body dimensions of horses plays a significant role in quality improvement, genetic breeding, health, and soundness. There has been significant advancement in the technology for acquiring stereoscopic images with a three-dimensional (3D) scanner. This study aimed to validate the accuracy of body measurements obtained from stereoscopic images taken with a 3D scanner. We manually took the following body measurements for 8 riding horses: height at the withers, height at the back, height at the croup, chest depth, width of the chest, width of the croup, width of the waist, girth circumference, cannon circumference, and body length. Using a versatile tablet-type 3D scanning device, we captured a 3D image of each horse. Relative errors varied from −1.37% to 6.25%. The correlation coefficient between manual and 3D measurements was significant for all body measurements (P
- Published
- 2021
6. Risk of adrenal insufficiency in patients with polymyalgia rheumatica versus patients with rheumatoid arthritis: A cross-sectional study
- Author
-
Akiko Kasahara, Takashi Kida, Aiko Hirano, Satoshi Omura, Hideaki Sofue, Aki Sakashita, Tomoya Sagawa, Mai Asano, Michiaki Fukui, Makoto Wada, Masataka Kohno, and Yutaka Kawahito
- Subjects
musculoskeletal diseases ,Arthritis, Rheumatoid ,Cross-Sectional Studies ,Rheumatology ,Adrenocorticotropic Hormone ,Polymyalgia Rheumatica ,Prednisolone ,Giant Cell Arteritis ,Humans ,Glucocorticoids ,Adrenal Insufficiency - Abstract
Objective To determine whether patients with polymyalgia rheumatica (PMR) are more susceptible to glucocorticoid-induced adrenal insufficiency, one of the barriers to glucocorticoid tapering strategies, compared to patients with rheumatoid arthritis (RA). Methods This cross-sectional study included PMR and RA patients who underwent adrenocorticotropic hormone (ACTH) tests to assess adrenal function. The eligibility criteria were as follows: previous use of prednisolone (PSL) ≥ 5 mg/day, use of PSL for six consecutive months before ACTH test, and current use of PSL at 5 mg/day or less. The association between disease type (PMR vs. RA) and insufficient adrenal response was assessed using logistic regression models. Results Twenty-six of 34 (76.5%) patients with PMR and 13 of 37 (35.1%) patients with RA had insufficient adrenal response. Compared to patients with RA, patients with PMR were more likely to have insufficient adrenal response, even after adjusting for age, sex, and PSL dose (adjusted odds ratio, 6.75; 95% confidence interval, 1.78–25.60). Conclusion Patients with PMR have a higher risk of glucocorticoid-induced adrenal insufficiency than patients with RA. Assessing the adrenal function in patients with PMR will contribute to establishing a more appropriate glucocorticoid reduction strategy.
- Published
- 2021
7. Risk of adrenal insufficiency in patients with polymyalgia rheumatica versus patients with rheumatoid arthritis: A cross-sectional study.
- Author
-
Akiko Kasahara, Takashi Kida, Aiko Hirano, Satoshi Omura, Hideaki Sofue, Aki Sakashita, Tomoya Sagawa, Mai Asano, Michiaki Fukui, Makoto Wada, Masataka Kohno, and Yutaka Kawahito
- Subjects
POLYMYALGIA rheumatica ,ADRENAL insufficiency ,RHEUMATOID arthritis ,CROSS-sectional method ,ADRENOCORTICOTROPIC hormone - Abstract
Objective: To determine whether patients with polymyalgia rheumatica (PMR) are more susceptible to glucocorticoid-induced adrenal insufficiency, one of the barriers to glucocorticoid tapering strategies, compared to patients with rheumatoid arthritis (RA). Methods: This cross-sectional study included PMR and RA patients who underwent adrenocorticotropic hormone (ACTH) tests to assess adrenal function. The eligibility criteria were as follows: previous use of prednisolone (PSL) ≥ 5 mg/day, use of PSL for six consecutive months before ACTH test, and current use of PSL at 5 mg/day or less. The association between disease type (PMR vs. RA) and insufficient adrenal response was assessed using logistic regression models. Results: Twenty-six of 34 (76.5%) patients with PMR and 13 of 37 (35.1%) patients with RA had insufficient adrenal response. Compared to patients with RA, patients with PMR were more likely to have insufficient adrenal response, even after adjusting for age, sex, and PSL dose (adjusted odds ratio, 6.75; 95% confidence interval, 1.78-25.60). Conclusion: Patients with PMR have a higher risk of glucocorticoid-induced adrenal insufficiency than patients with RA. Assessing the adrenal function in patients with PMR will contribute to establishing a more appropriate glucocorticoid reduction strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis
- Author
-
Eishi Ashihara, Keisuke Nishioka, Takashi Kida, Aiko Hirano, Kazuki Fujioka, Tomoya Sagawa, Jeffrey Strovel, Aki Sakashita, Mithun Raje, Akiko Kasahara, Masataka Kohno, Takuya Inoue, Yutaka Kawahito, Hidetake Nagahara, Makoto Wada, Shunya Kaneshita, Makoto Yoshioka, and Steven Fletcher
- Subjects
Pulmonary and Respiratory Medicine ,Pulmonary Fibrosis ,Bleomycin ,Transforming Growth Factor beta1 ,BET inhibitor ,Mice ,Paracrine signalling ,chemistry.chemical_compound ,Fibrosis ,Pulmonary fibrosis ,medicine ,Animals ,Pharmacology (medical) ,Autocrine signalling ,Lung ,Chemistry ,Biochemistry (medical) ,Nuclear Proteins ,Fibroblasts ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,Cancer research ,Myofibroblast ,Transcription Factors ,Transforming growth factor - Abstract
Pulmonary fibrosis is a progressive disease with poor prognosis and limited therapeutic options. In this study, we evaluated the potential therapeutic effects of CG223, a novel inhibitor of bromodomain and extra-terminal motif (BET) proteins, on pulmonary fibrosis by focusing on the transforming growth factor-β1 (TGF-β1) pathway. In a murine model of bleomycin-induced pulmonary fibrosis, CG223 attenuated fibrosis while reducing the infiltration of inflammatory cells into the lungs. Fibroblasts expressing BRD4, a member of the BET protein family, were enriched in the tissue regions corresponding to bleomycin-induced fibrotic lesions. Additionally, pulmonary fibroblasts isolated from bleomycin-instilled mice showed a significantly increased association of BRD4 with the promoters of two pro-fibrotic genes linked to the entry into the TGF-β1 autocrine/paracrine loop, thrombospondin 1 (Thbs1) and integrin β3 (Itgb3), as well as with the promoter of a myofibroblast marker gene, actin alpha 2 (Acta2). Subsequent in vitro studies with murine primary lung fibroblasts showed that the mRNA induction of Thbs1, Itgb3, and Acta2 by TGF-β1 can be inhibited by CG223 in a dose-dependent manner. Taken together, CG223-induced BRD4 inhibition suppressed lung fibrogenesis by affecting multiple genes, including those involved in the triggering of the TGF-β1 autocrine/paracrine loop.
- Published
- 2021
9. Risk Factors for Healthcare-Associated Infections After Pediatric Cardiac Surgery
- Author
-
Yuji Tominaga, Kazue Moon, Miyako Kyogoku, Takeshi Hatachi, Yoshiyuki Shimizu, Kazuya Tachibana, Yu Inata, Aiko Hirano, Kanako Isaka, and Muneyuki Takeuchi
- Subjects
Male ,medicine.medical_specialty ,Cardiotonic Agents ,pediatrics ,intensive care units ,medicine.medical_treatment ,Urinary system ,Dopamine ,030204 cardiovascular system & hematology ,Critical Care and Intensive Care Medicine ,Intensive Care Units, Pediatric ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Risk Factors ,Internal medicine ,medicine ,Humans ,Cardiac Intensive Care ,Risk factor ,Cardiac Surgical Procedures ,Child ,Retrospective Studies ,Mechanical ventilation ,Cross Infection ,business.industry ,Medical record ,Infant ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Cardiac surgery ,Pneumonia ,030228 respiratory system ,healthcare-associated infections ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business ,cardiac surgery - Abstract
Objectives Healthcare-associated infections after pediatric cardiac surgery are significant causes of morbidity and mortality. We aimed to identify the risk factors for the occurrence of healthcare-associated infections after pediatric cardiac surgery. Design Retrospective, single-center observational study. Setting PICU at a tertiary children's hospital. Patients Consecutive pediatric patients less than or equal to 18 years old admitted to the PICU after cardiac surgery, between January 2013 and December 2015. Interventions None. Measurements and main results All the data were retrospectively collected from the medical records of patients. We assessed the first surgery during a single PICU stay and identified four common healthcare-associated infections, including bloodstream infection, surgical site infection, pneumonia, and urinary tract infection, according to the definitions of the Centers for Disease Control and Prevention and National Healthcare Safety Network. We assessed the pre-, intra-, and early postoperative potential risk factors for these healthcare-associated infections via multivariable analysis. In total, 526 cardiac surgeries (394 patients) were included. We identified 81 cases of healthcare-associated infections, including, bloodstream infections (n = 30), surgical site infections (n = 30), urinary tract infections (n = 13), and pneumonia (n = 8). In the case of 71 of the surgeries (13.5%), at least one healthcare-associated infection was reported. Multivariable analysis indicated the following risk factors for postoperative healthcare-associated infections: mechanical ventilation greater than or equal to 3 days (odds ratio, 4.81; 95% CI, 1.89-12.8), dopamine use (odds ratio, 3.87; 95% CI, 1.53-10.3), genetic abnormality (odds ratio, 2.53; 95% CI, 1.17-5.45), and delayed sternal closure (odds ratio, 3.78; 95% CI, 1.16-12.8). Conclusions Mechanical ventilation greater than or equal to 3 days, dopamine use, genetic abnormality, and delayed sternal closure were associated with healthcare-associated infections after pediatric cardiac surgery. Since the use of dopamine is an easily modifiable risk factor, and may serve as a potential target to reduce healthcare-associated infections, further studies are needed to establish whether dopamine negatively impacts the development of healthcare-associated infections.
- Published
- 2018
10. Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
- Author
-
Amane Nakabayashi, Y. Kukida, Ken Murakami, Takahiro Seno, Aihiro Yamamoto, Yutaka Kawahito, Takashi Kida, Aiko Hirano, Wataru Fujii, Hidetake Nagahara, Masataka Kohno, Hiroyoshi Fujiwara, Kazuki Fujioka, and Ryo Oda
- Subjects
0301 basic medicine ,medicine.medical_specialty ,FRAX ,Bone density ,medicine.medical_treatment ,Osteoporosis ,Urology ,030209 endocrinology & metabolism ,Bone resorption ,03 medical and health sciences ,Glucocorticoid ,0302 clinical medicine ,Teriparatide ,medicine ,Bisphosphonate ,Femoral neck ,Multidisciplinary ,business.industry ,Research ,Once-weekly ,medicine.disease ,030104 developmental biology ,medicine.anatomical_structure ,Prednisolone ,business ,medicine.drug - Abstract
Background Patients with glucocorticoid-induced osteoporosis (GIOP) are at very high risk of fracture, and patients with severe GIOP often experience fractures during treatment with bisphosphonates. Teriparatide (TPTD) is the only currently available anabolic agent expected to be effective for GIOP. Once-weekly TPTD decreased bone resorption marker with primary osteoporosis different from daily TPTD, but it has not yet been tested with GIOP. Objectives To evaluate the efficacy of once-weekly TPTD for patients with GIOP and inadequate response to bisphosphonates. Methods Patients with GIOP and collagen diseases treated with prednisolone for at least 6 months with inadequate responses to bisphosphonates were administered once-weekly TPTD. Bone density of the lumbar spine and femoral neck, measured as percent young adult mean (YAM); serum concentrations of cross-linked N-terminal telopeptides of type I collagen (NTx), bone alkaline phosphatase (BAP), and calcium; and FRAX were measured at baseline and 6, 12 and 18 months after starting TPTD. Results Of the 12 GIOP patients with collagen diseases enrolled, nine (seven females, two males; mean age 57.4 ± 11.1 years) completed treatment, including six with systemic lupus erythematosus, two with rheumatoid arthritis, and one with adult onset still disease. Only one new fracture event, a lumbar compression fracture, occurred during the study period, although seven patients experienced eight fracture events within 18 months before starting TPTD (p = 0.04). Lumbar spine YAM significantly improved at 18 months (p = 0.04), whereas femoral neck YAM did not (p = 0.477). Serum NTx, BAP, Ca, and FRAX were not significantly affected by TPTD treatment. Conclusions Once-weekly TPTD reduces fracture events and increases bone density of the lumbar spine of GIOP patients with inadequate response to bisphosphonates.
- Published
- 2016
11. Risk Factors for Healthcare-Associated Infections After Pediatric Cardiac Surgery.
- Author
-
Takeshi Hatachi, Kazuya Tachibana, Yu Inata, Yuji Tominaga, Aiko Hirano, Miyako Kyogoku, Kazue Moon, Yoshiyuki Shimizu, Kanako Isaka, Muneyuki Takeuchi, Hatachi, Takeshi, Tachibana, Kazuya, Inata, Yu, Tominaga, Yuji, Hirano, Aiko, Kyogoku, Miyako, Moon, Kazue, Shimizu, Yoshiyuki, Isaka, Kanako, and Takeuchi, Muneyuki
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.